Deals and Financings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Roche and Illumina have entered a 15-year, non-exclusive partnership to expand access to next-generation sequencing- based testing in cancer care.
Latest From Deals
Smith & Nephew has acquired Tusker Medical for an undisclosed price. The acquisition comes just months after Tusker’s Tula system was approved by the FDA as a breakthrough device.
Illumina Inc. has agreed to pay $98m to terminate its merger agreement with Pacific Biosciences of California Inc. following opposition from antitrust regulators in the US and UK. See what Illumina CEO Francis deSouza said about it here.
Illumina had planned to acquire Pacific Biosciences to add the company's “long-read” gene sequencing systems to Illumina's own range of "short-read" technologies. However, the UK’s Competition and Markets Authority and the US Federal Trade Commission concluded that the deal would significantly reduce competition in the DNA sequencing market.
Laborie Medical Technologies has inked a $525m deal to buy obstetrics device maker Clinical Innovations. The acquisition adds a suite of neonatal and fetal care devices to Laborie’s existing obstetrics portfolio.
Johnson & Johnson is acquiring the remaining stake in Verb Surgical from Verily following a four-year partnership. The transaction is expected to close in the first half of 2020.
FujiFilm has signed an agreement to to buy Hitachi’s Diagnostic Imaging Business for $1.63bn to position itself among the top diagnostic imaging heavyweights.
For health-care providers and medtech manufacturers alike, the decade ahead will require a coming to terms with digital technologies and integrating new methods of payment. Quality of service delivery remains the market-entry criterion, but companies will have to adapt to evolving health-care models. The stakes are high. Will manufacturers be able to capitalize on the changes in a market that is more competitive and unpredictable than ever?
In an example of how so called "digital therapies" can augment traditional drug treatments, Swedish pharma company Orexo has secured exclusive US rights to an AI-based behavioral therapy for the treatment of alcohol use disorder (AUD).
The health-care sector remains ripe for investments, according to an expert panel of private equity investors. See what Steve Dyson, partner at UK private equity firm Apax Partners, said about it during a panel discussion at the recent Jefferies Healthcare Conference in London.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.